Standalone and Consolidated Results for FY 25-26
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts more than Nifty Microcap 250 and 2.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Makers Laboratories reported mixed results for FY 2025-26. Standalone revenue grew 17% to Rs 5,035 Lacs but the company swung to a net loss of Rs 172 Lacs compared to a profit of Rs 464 Lacs in the previous year. On a consolidated basis, revenue rose 16% to Rs 14,059 Lacs, with the chemical manufacturing segment (subsidiary Resonance Specialties) driving most of the group's profitability. However, consolidated net profit declined 28% to Rs 786 Lacs. The auditors issued an unmodified (clean) opinion on both standalone and consolidated results. Note 4 clarifies that the previous year's other income included a one-time Rs 1,010 Lacs profit from asset sales, making year-on-year comparisons less straightforward.
The standalone loss raises concerns about the pharmaceutical segment's standalone viability, though the consolidated picture remains profitable due to the chemical manufacturing subsidiary. Shareholders should watch if the standalone losses continue as this could indicate operational challenges in the core pharma business.